Biocon jumped nearly 3% in Monday’s trade after the company’s Pertuzumab biosimilar drug received EMA CHMP recommendation for breast cancer care.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.